ARTIMPLANT INTERIM REPORT JANUARY - JUNE 2008

ARTIMPLANT INTERIM REPORT JANUARY - JUNE 2008

Västra Frölunda, Sweden, August 7, 2008

• Net revenue for the second quarter amounted to SEK 3.1 million (4.7) and for
the first six months to SEK 5.2 million (8.7)*
• The net loss for the first quarter totaled SEK 6.2 million (4.8) and for the
first six months SEK 12.3 million (7.7)  
• Earnings per share for the second quarter amounted to SEK -0.10 (-0.08) and
for the first six months to SEK  -0.21 (-0.13)
• Sales of Artelon® Spacer totaled approximately 1,600 (2,100) units, of which
800 (800) were during the second quarter 
• Licensees have failed to meet the minimum volumes for the first half of the
year
• Sales have commenced in the USA through the Company's own sales organization
• Over 8,000 patients were treated with Artelon® implants up to and including
June 2008
• Clearance has been granted by the Swedish Medical Products Agency regarding
the Artelon® Bone Scaffold study for bone replenishment in the upper jaw and the
first patient has undergone surgery

N.B. This is a translation from Swedish. The Swedish version shall always take
precedence.

No telephone conference will be held by reason of this report. For further
information see www.artimplant.com.

* Figures in brackets refer to the corresponding period last year


For further information, please contact:
Hans Rosén, CEO, phone +46 (0)31-746 56 00, +46 (0)708 58 34 70,
hans.rosen@artimplant.com

Lars-Johan Cederbrant, CFO, phone +46 (0)31-746 56 54, +46 (0)703 01 68 54,
lars-johan.cederbrant@artimplant.com

Further information at www.artimplant.com where one also can subscribe to future
press releases;
www.artimplant.com/investors-media/subscribe-to-press-releases.html

About Artimplant
Artimplant is a biomaterials company focused on solutions to problems in
orthopedic and oral surgery. We restore health through the development,
production and marketing of degradable implants that regenerate body functions
and improve quality of life. Our products, made from Artelon®, meet unmet
clinical needs and are marketed in a growing number of therapy areas. Artimplant
produces implants for treatment of osteoarthritis in hands and feet, for
shoulder and other soft tissue injuries as well as oral surgery and veterinary
medical applications. 

Artimplant is a public company listed on the OMX Nordic Exchange Stockholm in
the Small Cap segment and in the healthcare sector.

Forward-looking statements
This press release contains forward-looking statements as defined in the U.S.
Private Securities Litigation Reform Act of 1995. Readers are cautioned not to
place undue reliance on these forward-looking statements. Actual results may
differ materially from those indicated by these forward-looking statements as a
result of risks and uncertainties impacting the Company's business including
increased competition; the ability of the Company to expand its operations and
to attract and retain qualified professionals; technological obsolescence;
general economic conditions; and other risks detailed from time to time in the
Company's filings.

This is information which Artimplant shall make public pursuant to the Swedish
Financial Instruments Act and the Swedish Securities Exchange and Clearing
Operations Act and/or stock market agreements. Information was made available
for publication on August 7, 2008 at 3pm (GMT+1).